Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-343

Revascor was never intended as a stand alone treatment. Instead it will likely be used alongside other agents that reduce non-fatal recurrent events if approved. Other treatments will be used to reduce non-fatal recurrent events (think maximal therapy), while our treatment will be used to reduce mortality rates, and is the only treatment currently shown to reduce mortality rates btw.

The reason why we didn't reduce non-fatal recurrent decompensated events is probably because patients in the placebo group were receiving maximal care or because our treatment doesn't reduce these events. We won't know until we get a look at the data, but I can see this as becoming part of the litany of treatments offered to heart failure patients, and it is sorely needed.